Journey Medical Corporation (NASDAQ:DERM) Receives Consensus Rating of “Hold” from Analysts

Shares of Journey Medical Corporation (NASDAQ:DERM) have received an average rating of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $12.1667.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Journey Medical in a report on Wednesday, January 21st.

Journey Medical Stock Performance

NASDAQ DERM opened at $7.73 on Tuesday. The firm has a market capitalization of $257.08 million, a P/E ratio of -22.09 and a beta of 0.81. The company has a current ratio of 1.42, a quick ratio of 1.12 and a debt-to-equity ratio of 0.75. The firm’s fifty day moving average price is $8.02 and its two-hundred day moving average price is $7.72. Journey Medical has a 1 year low of $4.85 and a 1 year high of $9.56.

Journey Medical (NASDAQ:DERM) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The firm had revenue of $17.63 million during the quarter, compared to the consensus estimate of $18.85 million. Journey Medical had a negative net margin of 14.58% and a negative return on equity of 39.94%. As a group, research analysts anticipate that Journey Medical will post -1.02 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Sheets Smith Investment Management bought a new stake in shares of Journey Medical during the 3rd quarter worth about $946,000. Essex Investment Management Co. LLC lifted its position in Journey Medical by 55.1% during the third quarter. Essex Investment Management Co. LLC now owns 354,021 shares of the company’s stock worth $2,521,000 after acquiring an additional 125,818 shares during the last quarter. Focus Partners Advisor Solutions LLC bought a new stake in shares of Journey Medical during the second quarter worth approximately $72,000. UBS Group AG grew its position in shares of Journey Medical by 99.9% in the fourth quarter. UBS Group AG now owns 290,226 shares of the company’s stock valued at $2,238,000 after purchasing an additional 145,006 shares during the last quarter. Finally, Salem Investment Counselors Inc. grew its position in shares of Journey Medical by 18.2% in the fourth quarter. Salem Investment Counselors Inc. now owns 14,300 shares of the company’s stock valued at $110,000 after purchasing an additional 2,200 shares during the last quarter. 7.25% of the stock is owned by institutional investors and hedge funds.

About Journey Medical

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.